Invitrogen

Aurora A Polyclonal Antibody

Advanced Verification

This Antibody was verified by Cell treatment to ensure that the antibody binds to the antigen stated.

1 Reference

View all (41) Aurora A antibodies

Datasheet

Protocols

Questions & Answers

Tech Support

Datasheet

Protocols

Questions & Answers

Tech Support

Product Image Gallery

Aurora A Antibody in Immunocytochemistry (ICC/IF) — Immunofluorescence analysis of Aurora A was performed using 70% confluent log phase MCF7 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 2% BSA for 1 hour at room temperature. The cells were labeled with Aurora A Polyclonal Antibody (Product # PA1-26351) at 5 µg/mL concentration in 0.1% BSA, incubated at 4 degree celsius overnight (Panel a: green). Mitotic chromosomes (Panel b: blue) were stained with ProLong™ Diamond Antifade Mountant with DAPI (Product # P36962). F-actin (Panel c: red) was stained with Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing mitotic cells with AuroraA expression concentrated at the spindle poles. Panel e represents the resting cells showing cytoplasmic expression of AuroraA . Panel f represents control cells with no primary antibody to assess background. The images were captured at 60X magnification.

Aurora A Antibody in Western Blot (WB) — Western blot analysis was performed on modified whole cell extracts (1% SDS- 30 µg lysates) of HCT 116 (Lane 1), HCT 116 treated with Paclitaxe l(100nM for 18 hrs) (Lane 2), HT-29 (Lane 3), HT-29 treated with Paclitaxel (100nM, 18hrs) (Lane 4), SK-BR-3 (Lane 5) and SK-BR-3 treated with Nocodazole (100ng/mL, 16 hrs) (Lane 6). The blot was probed with Anti-Aurora A Polyclonal Antibody (Product # PA1-26351, 1 µg/mL) and detected by chemiluminescence using Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A27036, 0.25 µg/mL, 1:4000 dilution). A 48 kDa band corresponding to AuroraA were observed across the cell lines tested, with an increase in expression upon treatment.

Aurora A Antibody in Immunoprecipitation (IP) — IP analysis of 35S-Met-labeled whole cell lysate transfected with a human Aurora A expression construct using (Product # PA1-26351) Aurora A Polyclonal Antibody.
IP reaction : 2-10 µg/mg lysate.

Aurora A Antibody — Altered expression of target protein upon cell treatment demonstrates antibody specificity. Immunofluorescence analysis of AuroraA using Aurora A Polyclonal Antibody (Product # PA1-26351) shows cytoplasmic expression, concentrated at the spindle poles in mitotic MCF7 cells, and cytoplasmic staining in resting cells.

Product Details

PA1-26351

Applications

Tested Dilution

Publications

Western Blot (WB)

1 µg/mL

Immunohistochemistry (Paraffin) (IHC (P))

0.4-1 µg/mL

Immunocytochemistry (ICC/IF)

5 µg/mL

Immunoprecipitation (IP)

2-10 µg/mg of lysate

View 1 publication 1 publication

Product Specifications

Species Reactivity

Human

Published species

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Synthetic peptide, conjugated to KLH, corresponding to a portion of human Serine/Threonine Kinase 15 encoded within exon 5.

Conjugate

Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

tris citrate/tris phosphate, pH 7-8

Contains

0.09% sodium azide

Storage conditions

4° C, do not freeze

RRID

AB_779336

Product Specific Information

PA1-26351 detects Aurora A from human samples.

Target Information

AURKA (Aurora A) is a serine/threonine kinase that regulates mitosis by association in vivo with centrosomes. Overexpression of AURKA is observed in many types of cancer. Aurora A plays a role in cell cycle regulation during anaphase and/or telophase, in relation to the function of the centrosome/spindle pole region during chromosome segregation. Aurora A plays a key role during tumor development and progression and is overexpressed in many human cancers including breast, ovarian and colorectal. Aurora A is viewed as a potential target for anticancer drug treatment. Tissue specificity: Highly expressed in testis and weakly in skeletal muscle, thymus and spleen.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

A kinase-independent function for AURORA-A in replisome assembly during DNA replication initiation.

Nucleic acids research

Guarino Almeida E,Renaudin X,Venkitaraman AR

PA1-26351 was used in Immunoprecipitation to report a kinase-independent function for AURORA-A kinase(AURKA) in DNA replication initiation whose inhibition through a class of allosteric inhibitors opens avenues for cancer therapy.

Thu Aug 20 00:00:00 EDT 2020

Bioinformatics

Protein Aliases: ARK-1; AURAK; Aurora 2; Aurora A Kinase; Aurora kinase A; aurora/IP; aurora/IPL1-like kinase; Aurora/IPL1-related kinase 1; AURORA2; Breast tumor-amplified kinase; EC 2.7.11.1; hARK1; Ipl1- and aurora-related kinase 1; IPL1-related kinase; MGC34538; OTTHUMP00000031341; OTTHUMP00000166072; protein phosphatase 1, regulatory subunit 47; RP5-1167H4.6; serine/threonine protein kinase 15; Serine/threonine-protein kinase 15; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase aurora-A; Serine/threonine-protein kinase Ayk1

Gene Aliases: AIK; AIRK1; ARK1; AURA; AURKA; AYK1; BTAK; IAK1; PPP1R47; STK15; STK6; STK7

UniProt ID: (Human) O14965

Entrez Gene ID: (Human) 6790

Molecular Function: non-receptor serine/threonine protein kinase